Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
ANI Pharmaceuticals Reports Third Quarter and Year-To-Date 2015 Results and Highlights
November 3, 2015 8:00 AM ESTBAUDETTE, Minn., Nov. 3, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial results for the three and nine months ended September 30, 2015 and updated its financial guidance for 2015. The Company will host its earnings conference call this morning, November 3, 2015, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (844) 295-8236. The conference ID is 59208657.
Arthur S. Przybyl, President and CEO, stated,
"We are pleased to report a strong third quarter, with increases over the prior year in revenue,... More
ANI Pharmaceuticals Announces Launch of Vancomycin Capsules
November 2, 2015 8:00 AM ESTBAUDETTE, Minn., Nov. 2, 2015 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced the launch of Vancomycin HCl 125mg and 250mg capsules indicated for treatment of C. difficile-associated diarrhea. The overall US market for Vancomycin HCl Capsules is approximately $113 million, per IMS Health.
Arthur S. Przybyl, President and Chief Executive Officer said, "We are pleased to announce the launch of our authorized generic to Vancocin, which replaces the authorized generic previously on the market. This is the second of four generic products we plan to launch before the end of... More
